Rechallenging with immune checkpoint inhibition after a treatment-limiting immune-related adverse event.

3053Background: Immune checkpoint inhibition (ICI) with cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death 1 (PD-1), or programmed death ligand-1 (PD-L1) blockade can be associated with th...